The Food and Drug Administration (FDA) today approved a first-of-a-kind medical device for the treatment of babies born with moderate to severe hypoxic-ischemic encephalopathy (HIE), a potentially fatal injury to the brain caused by low levels of oxygen.
The Food and Drug Administration (FDA) today approved Colazal (balsalazide disodium) for the treatment of mildly to moderately active ulcerative colitis in patients 5 to 17 years of age.
Newly approved medications for restless leg syndrome may only be effective for a time, suggest movement disorder neurologists from the University of Rochester Medical Center. If taken too long, in some cases the drugs can actually backfire, causing symptoms to worsen. Rochester specials suggest that treatment that rotates through different types of medications may be needed for many patients.
Engineers are designing new high-tech medical tools to equip the operating room of the future, in an effort to help doctors treat patients more safely and effectively and allow them to perform surgical tasks that are nearly impossible today.
A different approach to treating urinary tract infections (UTIs) could defeat the bacteria that cause the infections without directly killing them, a strategy that could help slow the growth of antibiotic-resistant infections. Researchers at Washington University School of Medicine in St. Louis have been working to create pharmaceuticals that essentially “defang” the bacteria by preventing them from assembling pili, microscopic hairs that enable the bacteria to invade host cells.
The widely used breast cancer drug tamoxifen (Nolvadex), which can become less effective over time, might retain its full strength indefinitely if used along with a second drug, according to new research in mice conducted by investigators from the National Cancer Institute, part of the National Institutes of Health, and their partners.
The Food and Drug Administration (FDA) is alerting health care professionals and patients treated with Rituxan (rituximab) to reports of an emerging risk of a serious side effect in patients receiving or who have used Rituxan.
Patients are to be able to access a website on the performance of private hospitals.
Asthmatics and people prone to respiratory problems should have an action plan for the fire season to help them breathe easier over summer.
The Australian Government has expanded eligibility for the osteoporosis medication alendronate under the Pharmaceutical Benefits Scheme (PBS).